[1]张 林,白 俐.银杏达莫对AECOPD合并肺动脉高压的影响[J].医学信息,2019,32(14):83-86.[doi:10.3969/j.issn.1006-1959.2019.14.026]
　ZHANG Lin,BAI Li.Effect of Yinxingdamo on AECOPD with Pulmonary Hypertension[J].Journal of Medical Information,2019,32(14):83-86.[doi:10.3969/j.issn.1006-1959.2019.14.026]
点击复制

银杏达莫对AECOPD合并肺动脉高压的影响()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年14期
页码:
83-86
栏目:
论著
出版日期:
2019-07-15

文章信息/Info

Title:
Effect of Yinxingdamo on AECOPD with Pulmonary Hypertension
文章编号:
1006-1959（2019）14-0083-04
作者:
张 林; 白 俐
广东药科大学附属第二医院/广州新海医院重症医学科，广东 广州 510300
Author(s):
ZHANG Lin; BAI Li
Department of Critical Care Medicine,the Second Affiliated Hospital of Guangdong Pharmaceutical University/ Guangzhou Xinhai Hospital,Guangzhou 510300,Guangdong,China
关键词:
慢性阻塞性肺疾病急性加重期; 银杏达莫; 白细胞介素-6; 肿瘤坏死因子-α; 内皮素-1; 一氧化氮
Keywords:
Key words：Acute exacerbation of chronic obstructive pulmonary disease; Yinxingdamo; Interleukin-6;  Tumor necrosis factor-α; Endothelin-1; Nitric oxide
分类号:
R285；R544
DOI:
10.3969/j.issn.1006-1959.2019.14.026
文献标志码:
A
摘要:
目的 探讨银杏达莫对慢性阻塞性肺疾病急性加重期（AECOPD）合并肺动脉高压的影响及其可能机制。方法 选取2015年6月~2018年3月我院收治的120例AECOPD伴肺动脉高压患者，随机分为对照组和治疗组，每组60例。对照组予常规治疗，治疗组在对照组基础上加用银杏达莫注射液静滴，持续2周。比较两组患者治疗前后肺功能（FEV1、FEV1/FCV）、肺动脉收缩压（PASP）及舒张压（PADP）水平、血清中炎症因子（IL-6、TNF-α）及血管活性因子（ET-1、NO）浓度。结果 两组患者治疗后FEV1、FEV1/FCV水平均较治疗前升高（P＜0.05）；治疗后，治疗组FEV1、FEV1/FCV分别为（2.02±0.53）L和（56.57±7.11）%，高于对照组的（1.85±0.46）L和（54.87±9.18）%（P＜0.05）；PASP及PADP水平均较治疗前下降（P＜0.05）；治疗组PASP及PADP分别为（48.92±10.53）mmHg和（22.13±3.16）mmHg，低于对照组的（57.35±11.46）mmHg和（26.73±4.27）mmHg（P＜0.05）； IL-6、TNF-α浓度均较治疗前下降（P＜0.05）；治疗组IL-6、TNF-α分别为（3.24±1.67）ng/L和（56.41±5.53）ng/ml，低于对照组的（4.64±1.52）ng/L和（63.77±7.65）ng/ml（P＜0.05）；两组患者治疗后ET-1浓度较治疗前降低，NO浓度较治疗前升高（P＜0.05）；治疗后两组比较，治疗组ET-1为（75.25±9.69）ng/L，低于对照组的（83.47±11.78）ng/L，治疗组NO为（56.41±8.93）μmol/L，高于对照组的（47.77±8.22）μmol/L（P＜0.05）。结论 银杏达莫能改善慢性阻塞性肺疾病急性加重期患者肺功能及肺动脉高压情况，其机制可能与降低炎症反应及影响血管活性因子相关。
Abstract:
Abstract：Objective To investigate the effect of Yinxingdamo on acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with pulmonary hypertension and its possible mechanism.Methods A total of 120 patients with AECOPD and pulmonary hypertension admitted to our hospital from June 2015 to March 2018 were randomly divided into control group and treatment group, with 60 cases in each group. The control group was given conventional treatment, and the treatment group was given an intravenous infusion of Yinxingdamo injection on the basis of the control group for 2 weeks. Pulmonary function (FEV1, FEV1/FCV), pulmonary systolic pressure (PASP) and diastolic blood pressure (PADP) levels, serum inflammatory factors (IL-6, TNF-α) and the concentration of vasoactive factors (ET-1, NO).Results The levels of FEV1 and FEV1/FCV in the two groups were higher than those before treatment (P<0.05). After treatment, the FEV1 and FEV1/FCV in the treatment group were (2.02±0.53)L and (56.57±7.11)%, respectively. The levels of PASP and PADP were lower than those in the control group (1.85±0.46)L and (54.87±9.18)% (P<0.05). The PASP and PADP levels were lower than those before treatment (P<0.05). The PASP and PADP in the treatment group were (48.92±10.53) mmHg and (22.13±3.16) mmHg, lower than (57.35±11.46) mmHg and (26.73±4.27) mmHg (P<0.05) in the control group; IL-6 and TNF-α concentrations were lower than before treatment (P<0.05); IL-6 and TNF-α in the treatment group were (3.24±1.67) ng/L and (56.41±5.53) ng/ml, respectively (4.64±1.52) ng/L and (63.77±7.65) Ng/ml (P<0.05); the concentration of ET-1 in the two groups was lower than that before treatment, and the concentration of NO was higher than that before treatment (P<0.05). After treatment, the ET-1 in the treatment group was (75.25±9.69) ng/L, which was lower than that of the control group (83.47±11.78) ng/L, the NO of the treatment group was (56.41±8.93) μmol/L, which was higher than that of the control group (47.77±8.22) μmol/L (P<0.05). Conclusion Yinxingdamo can improve pulmonary function and pulmonary hypertension in patients with acute exacerbation of chronic obstructive pulmonary disease. The mechanism may be related to the reduction of inflammatory response and the influence of vasoactive factors.

参考文献/References:

[1]曹秀丽.慢性阻塞性肺疾病并发肺动脉高压与CRP、IL-6、BNP的相关性研究[D].河北医科大学,2016. [2]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)(一)[J].全科医学临床与教育,2013,11(5):484-491． [3]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.肺动脉高压筛查诊断与治疗专家共识[J].中华心血管病杂志,2007,35(11):979-987． [4]Meysman M,Pipeleers-Marichal M,Geers C,et al.Severe right heart failure in a patient with chronic obstuctive lung disease:a diagnostic challenge[J].Indian J Chest Dis Allied Sci,2013,55(3):159-162． [5]武红莉,田瑞雪,叶青,等.B型脑钠肽、超敏C反应蛋白、纤维蛋白原、D-二聚体及血气分析在慢性阻塞性肺疾病急性加重期合并肺动脉高压患者中的表达[J].实用临床医药杂志,2018,22(3):32-33,37. [6]贾佳,程德云.慢性阻塞性肺疾病相关肺动脉高压发病机制[J],临床荟萃,2016,31(3):345-348． [7]何海燕,陶一江,陈建荣,等.慢性阻塞性肺疾病合并肺动脉高压患者血清及呼出气冷凝液中TNF-α的检测[J].江苏医药,2010,36(23):2774-2776． [8]Sutendra G,Dromparis P,Bonnet S,et al.Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNF-αcontributes to the pathogenesis of pulmonary arterial hypertension[J].Mol Med (Berl),2011(89):771-783． [9]毛琴,方蒡,屈晓雯,等.慢性阻塞性肺疾病并肺动脉高压与炎性因子的关系及疗效观察[J].临床医药文献电子杂志,2016, 3(35):6936-6937． [10]张松,李小波,张蓉映,等.辛伐他汀对COPD合并肺心病患者肺功能肺动脉压力及CRP的影响[J].浙江临床医学,2017,19(2):298-299． [11]Sakao S,Voelkel NF,Tatsumi K.The vascular bed in COPD:pulmonary hypertension and pulmonary vascular alterations[J].Eur Res Rev,2014,23(133):350-355. [12]马华,曹丽娜,蒋培培,等.丹参川芎嗪对野百合碱诱导的肺动脉高压大鼠ET-1、 NO和RVHI的影响[J].徐州医学院学报,2014,34(8):520-522． [13]郑玉兰,付文荣,曹锋生.丹参川芎嗪对慢性阻塞性肺疾病急性加重合并呼吸衰竭患者肺功能及炎症因子的影响[J].中国老年学杂志,2015(24):7109-7111． [14]莫健平.中西医结合治疗慢性阻塞性肺疾病伴呼吸衰竭疗效观察[J].实用中医药杂志,2016,32(4):348-349． [15]陈金亮,陈建荣,蔡映云.COPD患者呼出气冷凝液中8-异前列腺素的检测及其意义[J].临床肺科杂志,2011,16(3):341-343． [16]Lai YC,Potokak KC,Champion Hc,et al.Pulmonary arterial hypertension:the clinical syndrome[J].CirRes,2014,115(1):115-130 [17]夏倩,张念,罗光伟.丹参川芎嗪注射液对慢性阻塞性肺病患者D-二聚体的影响[J].内蒙古中医药,2014,33(26):33-34. [18]蔡林再,王成存,谢五菊.慢性阻塞性肺疾病患者外周血脂肪炎症因子一氧化氮合成酶水平及其意义[J].山西医药杂志,2015,44(24):2847-2849． [19]赵德强,金惠根,刘宗军,等．银杏达莫注射液对急性心肌梗死患者直接经皮冠状动脉成形术后心肌灌注和临床预后的影响[J].上海医学,2010,33(10):930-933. [20]李志强.依达拉奉联合银杏达莫对血管性认知功能障碍患者治疗作用的研究[J].实用临床医药杂志,2012,15(21):115-117． [21]孙金菊,孙淑娟.银杏达莫注射液对慢性阻塞性肺疾病急性加重期患者的心肺保护作用研究[J].中药材[J],2018,7(41):1751-1754.

相似文献/References:

[1]吴君华,吴友茹,李 丹.血清降钙素原在AECOPD抗感染治疗中的应用价值研究[J].医学信息,2018,31(02):74.[doi:10.3969/j.issn.1006-1959.2018.02.025]
　WU Jun-hua,WU You-ru,LI Dan.Study on the Application Value of Serum Calcitonin in the Anti Infection Treatment of AECOPD[J].Journal of Medical Information,2018,31(14):74.[doi:10.3969/j.issn.1006-1959.2018.02.025]
[2]许 俊.慢性阻塞性肺疾病急性加重期与慢性阻塞性肺疾病并发社区获得性肺炎患者的临床对比[J].医学信息,2018,31(22):118.[doi:10.3969/j.issn.1006-1959.2018.22.033]
　XU Jun.Clinical Comparison of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Chronic Obstructive Pulmonary Disease Complicated with Community Acquired Pneumonia[J].Journal of Medical Information,2018,31(14):118.[doi:10.3969/j.issn.1006-1959.2018.22.033]
[3]李 丹.丁苯酞联合银杏达莫治疗急性脑梗死的疗效[J].医学信息,2020,33(05):161.[doi:10.3969/j.issn.1006-1959.2020.05.053]
　LI Dan.Efficacy of Butylphthalide Combined with Ginkgo Leaf Extract and Dipyridamole in the Treatment of Acute Cerebral Infarction[J].Journal of Medical Information,2020,33(14):161.[doi:10.3969/j.issn.1006-1959.2020.05.053]
[4]肖慧琴.平喘固本汤合补肺汤联合头孢他啶治疗AECOPD肺肾气虚证的临床疗效及不良反应[J].医学信息,2025,38(12):112.[doi:10.3969/j.issn.1006-1959.2025.12.023]
　XIAO Huiqin.Clinical Efficacy and Adverse Reactions of Pingchuan Guben Decoction and Bufei Decoction Combined with Ceftazidine in the Treatment of AECOPD with Lung and Kidney Qi Deficiency Syndrome[J].Journal of Medical Information,2025,38(14):112.[doi:10.3969/j.issn.1006-1959.2025.12.023]
[5]黄炜斌.苏子降气汤合三子养亲汤加减治疗慢性阻塞性肺疾病急性加重的临床疗效及对PEF、FVC的影响[J].医学信息,2025,38(15):76.[doi:10.3969/j.issn.1006-1959.2025.15.015]
　HUANG Weibin.Clinical Effect of Modified Suzi Jiangqi Decoction and Sanzi Yangqin Decoction in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and its Effect on PEF and FVC[J].Journal of Medical Information,2025,38(14):76.[doi:10.3969/j.issn.1006-1959.2025.15.015]
[6]丁红铃.WBC、hs-CRP、SAA、NLR在慢性阻塞性肺疾病稳定期及急性加重期患者中的表达分析[J].医学信息,2025,38(20):135.[doi:10.3969/j.issn.1006-1959.2025.20.029]
　DING Hongling.Expression of WBC, hs-CRP, SAA and NLR in Patients with Stable and Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2025,38(14):135.[doi:10.3969/j.issn.1006-1959.2025.20.029]
[7]杨博鸣.小青龙汤与吸入用乙酰半胱氨酸溶液在慢性阻塞性肺疾病急性加重期中的治疗作用[J].医学信息,2025,38(22):114.[doi:10.3969/j.issn.1006-1959.2025.22.021]
　YANG Boming.Therapeutic Effect of Xiaoqinglong Decoction and Acetylcysteine Solution for Inhalationon Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2025,38(14):114.[doi:10.3969/j.issn.1006-1959.2025.22.021]

更新日期/Last Update: 2019-07-15